Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $508.34 -1.55%
EPS Growth %: -0.6%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -0.6%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.52, $0.25 better than the analyst estimate of $4.27. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.94 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Faraday Future unveils nine robot models, prices start at $9,990
- Empire Petroleum (EP) files $150M mixed shelf
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
